Sign In
Buy SANA
$3.12
-0.120 (-3.70%)
At Close: Jun 03, 2026
Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference
04:05pm, Monday, 24'th Feb 2025
SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca
There May Still Be Time to Get in on These 3 Trending Biotechs
08:15am, Monday, 20'th Jan 2025
Despite the strength of the economy overall, 2024 was a challenging year for the biotech industry. The high cost of borrowing—particularly prior to the Fed's first rate cut in several years in Septe
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
12:00pm, Saturday, 18'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
08:45pm, Thursday, 16'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
12:00pm, Friday, 10'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advi
SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data
11:21am, Friday, 10'th Jan 2025
Sana stock soars in a week following positive initial data from a first-in-human study of investigational cell therapy, UP421, in diabetes patients.
Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
04:05pm, Wednesday, 08'th Jan 2025
SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
12:00pm, Wednesday, 08'th Jan 2025
NEW YORK , Jan. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advise
Sana Biotechnology skyrockets 200% on positive diabetes study data
11:32am, Wednesday, 08'th Jan 2025
Sana Biotechnology Inc skyrocketed over 200% on Wednesday after unveiling positive results from its first in-human diabetes trial. No safety issues were observed four weeks after transplanting Sana's
Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success
10:30am, Wednesday, 08'th Jan 2025
Sana Biotechnology, Inc. stock will be surging today after the company showed it can safely administer its allogeneic cell therapy for diabetes to a patient with no immunosuppression. Engineered cells
Sana Biotechnology Stock Surges Over 200% On Wednesday - Here's Why
09:27am, Wednesday, 08'th Jan 2025
On Tuesday, Sana Biotechnology Inc SANA released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) t
Citi keeps $15 target on Sana, says data 'potentially transformative'
09:11am, Wednesday, 08'th Jan 2025
Citi says that while the wait for Sana Biotechnology's initial type 1 diabetes data was long, the "reward was well worth it as Sana has delivered what looks to be potentially transformative data," the
H.C. Wainwright ups Sana target after 'best case scenario' data
09:08am, Wednesday, 08'th Jan 2025
H.C. Wainwright raised the firm's price target on Sana Biotechnology to $11 from $8 and keeps a Buy rating on the shares. The firm increased its probability of sucess for SC451 to 15% from 10% based o
This Biotech Stock Just Soared 240%. Why It Can Go Higher.
07:25am, Wednesday, 08'th Jan 2025
The shares are at about $5 now, and strategists see a chance they could go to $10.
First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression
